secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K/A
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001104659-22-028676
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hookipa restates Gilead deal, gets $35M equity; HIV R&D expanded
----------------------------------------------------------------

- Hookipa assumes additional HIV development responsibility under restated collaboration agreement.
- Gilead to purchase up to $35 million of Hookipa common stock to support increased HIV R&D.
- Restated agreement covers HBV and HIV vaccine programs using Hookipa's arenavirus technology.
- Financial milestones and royalties are redacted but original 2018 deal amended.
- Full collaboration agreement filed as Exhibit 10.1 to Form 8-K/A.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000110465922028676/0001104659-22-028676-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000110465922028676/tm227839d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-028676

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer